Primary Appointment:
 Department of Medicine

GEBS Cluster Affiliations:
 IMV - Immunology, Microbiology, and Virology

University of Rochester
School of Medicine and Dentistry
601 Elmwood Ave, Box 689
Rochester, New York 14642

Phone: (585) 275-5871
E-Mail: richard_reichman@urmc.rochester.edu

Human Papillomavirus and Human Immunodeficiency Virus Infections

Human Papillomavirus (HPV) Infections: Studies of HPV infections utilize recombinant DNA produced virus-like particles (VLPs), animal models, and patients enrolled in clinical trials to investigate pathogenesis, efficacy of antiviral drugs, and human immune responses to HPV. Recently initiated studies focus on the interactions between AIDS and HPV infection by carefully following cervical disease in women with coincident human immunodeficiency virus (HIV) infection. In collaboration with Drs. William Bonnez and Robert C. Rose.

Human Immunodeficiency Virus (HIV) Infections and AIDS: Using HIV isolates obtained from patients enrolled in clinical trials of new modes of treatment for AIDS, ongoing studies examine mechanisms of HIV resistance to antiretroviral drugs. Techniques utilized include tissue culture and nucleic acid sequencing. In collaboration with Dr. Lisa Demeter.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 350:1850-61, 2004.

Shiramizu B, Theodore D, Bassett R, Coel M, Sherman KE, Glesby MJ, Chow D, Alston B, Colquhoun D, Merigan Jr TC, Reichman RC, Berggren R, Burning WJ, Brobst S. Correlation of Single Photon Emission Computed Tomography Parameters as a Noninvasive Alternative to Liver Biopsies in Assessing Liver Involvement in the Setting of HIV and Hepatitis C Virus Coinfection: A Multicenter Trial of the Adult AIDS Clinical Trials Group. J Acquir Immune Defic Syndr 33:329-335, 2003.

Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 52:918-25, 2003.

Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC. A Phase 1 Study of a Recombinant Viruslike Particle Vaccine against Human Papillomavirus Type 11 in Healthy Adult Volunteers. J Infect Dis. 183:1485-93, 2001.

Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol. 74:8390-401, 2000.

Dykes C, Mootsikapun P, Dexter A, Berrios L, Chiulli M, Reichman RC, Demeter LM. Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors. J Infect Dis. 182:316-20, 2000.

Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res. 2000 45:47-58, 2000.

Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 44:794-7, 2000.